Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA-damage response pathways triggered by viral replication.

Alison Sinclair1, Sarah Yarranton, Celine Schelcher

  • 1School of Life Sciences, University of Sussex, Brighton, BN1 9QG, UK. a.j.sinclair@sussex.ac.uk

Expert Reviews in Molecular Medicine
|March 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a new diagnostic ELISA to detect anti-JCV antibodies in serum of patients with multiple sclerosis considering or receiving treatment with natalizumab.

Multiple sclerosis and related disorders·2026
Same author

Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis.

Drugs in R&D·2025
Same author

QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies.

Annals of internal medicine·2021
Same author

Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.

Clinical pharmacology in drug development·2021
Same author

A Comparison of Patient-Reported Outcome Measures of Quality of Life By Dialysis Modality in the Treatment of Kidney Failure: A Systematic Review.

Canadian journal of kidney health and disease·2020
Same author

A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.

British journal of clinical pharmacology·2020

Viruses like HIV and EBV manipulate DNA repair pathways. Inhibiting these pathways may offer new antiviral treatments by disrupting viral replication.

Area of Science:

  • Virology
  • Molecular Biology
  • Genetics

Background:

  • Distinct viruses, including human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV), activate cellular DNA-damage response (DDR) pathways during replication.
  • Key DDR mediators implicated include DNA-dependent protein kinase, ataxia-telangiectasia mutated (ATM), and ataxia-telangiectasia and Rad3-related (ATR).

Purpose of the Study:

  • This review focuses on the intricate interplay between HIV and EBV replication and cellular DNA repair mechanisms.
  • To explore how viral replication impacts DNA repair pathways and to identify potential therapeutic targets within the DDR.

Main Methods:

  • Literature review focusing on studies investigating viral interactions with DNA-damage response pathways.
  • Analysis of mechanisms by which viruses like HIV and EBV modulate cellular DNA repair and signaling.

Related Experiment Videos

Main Results:

  • Viral replication, particularly of HIV and EBV, is shown to activate cellular DNA repair and recombination enzymes, which can be beneficial for the virus.
  • Inhibition of ATM and ATR pathways has been demonstrated to impede HIV replication, suggesting their critical role.
  • Viruses can actively subvert the DDR by suppressing downstream signaling from sensors, as observed with EBV, potentially to evade host defenses or promote survival.

Conclusions:

  • Activation of DNA-damage response pathways presents a dual role in viral infections, potentially aiding replication while also risking host cell apoptosis.
  • Viruses exhibit sophisticated strategies to manipulate these pathways for their own benefit.
  • Targeting DNA-damage response pathways with novel small-molecule inhibitors represents a promising therapeutic strategy for treating viral infections like HIV and EBV.